



Benefits of EMBLEM™ S-ICD for Primary Prevention Patients



TABLE OF CONTENTS

Goals for Primary Prevent Patients	2
Proven Efficacy	3
Reduced Risk	4
Infections	5
Tricuspid Regurgitation	6
What about ATP?	7
What if patient develops need for Brady Pacing?	8
Importance of Monitoring Patients For New Onset AFIB	9
EMBLEM™ MRI S-ICD Protection With Reduced Risk	10
References	11

GOALS FOR PRIMARY PREVENTION PATIENTS

Prevent Sudden Cardiac Death With Lowest Risk

When Primary Prevention patients meet the indications for an ICD, the goal should be to prevent sudden cardiac death with the least amount of risk. Several large studies, including 2 prospective, randomized trials, have shown that the S-ICD prevents sudden cardiac death in approximately 98% of patients, which is similar to transvenous ICDs (TV-ICDs), while avoiding the serious complications that occur with TV-ICDs.¹⁻⁷ The EMBLEM™ S-ICD will be upgradeable to deliver painless ATP and/or VVIR pacing upon FDA approval of the EMPOWER™ Leadless Pacemaker (LP)* & Modular CRM (mCRM™) system*^{8,9}, making S-ICD an ideal option for Primary Prevention patients, including patients in their 50s or 60s with ischemic heart disease.

People with heart failure are living longer

With earlier diagnosis and advances in heart failure therapy, patients with heart failure are living longer.¹⁰ This longer life expectancy for heart failure patients increases the risk of complications and infections for patients with a TV-ICD.

Serious complication rate with TV-ICD
6.8-24% at 10y


In a study with over
28,000 TV-ICD implants

 nearly **1 out of 4** patients with a TV-ICD had mechanical complications and **close to 7%** had an infected TV-ICD at 10 years.¹¹

The S-ICD **avoids many serious complications** that occur with TV-ICDs



20 years With over **20 years** of data^{1-9, 12-15}, the S-ICD has demonstrated **lower risk for many serious complications** that occur with TV-ICDs.




*Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.

PROVEN EFFICACY

S-ICD prevents sudden cardiac death

The S-ICD has a conversion efficacy of 98% out to 5 years of follow-up. In long-term follow-up studies, the S-ICD has demonstrated it prevents sudden cardiac death that is comparable to the data of TV-ICDs.^{2-5, 16-18}



NOTE: Results from different clinical studies are not directly comparable and information is provided for educational purposes only. Only first shock was reported for SCD-HeFT, PainFree RX II, and MADIT-CRT.


REDUCED RISK

S-ICD reduces risk for complications

The PRAETORIAN prospective, randomized trial compared S-ICD and TV-ICD complication rates over a 4-year follow-up period.¹ The median patient age was 63 years, 82% of patients had a primary prevention indication and 68% had ischemic heart disease.¹ Compared to TV-ICD patients, fewer S-ICD patients had a complication requiring invasive intervention, including systemic infection. The authors recommend including these results during the Shared Decision Making discussion with patients.¹

S-ICD patients had a lower risk for


- Lead-related complications¹
- Systemic infections¹
- Invasive interventions¹



INFECTIONS

Infections with an S-ICD are easier to manage than infections with a transvenous ICD

While infection rates are similar, infections are easier and safer to manage with an S-ICD versus a TV-ICD. Infections can occur with any ICD; however, serious complications occurred in 10% of patients with a 4% mortality rate in data from over 59,000 TV-ICD extractions in patients who had an infection.¹⁹ In a systematic review of 30 publications with 207 S-ICD lead extractions, there were **ZERO complications** and **ZERO deaths**.²⁰



Hosseini, S.M. et al J Am Coll Cardiol EP.2019;5(12):1450-8


TRICUSPID REGURGITATION

Recent data shows transvenous leads worsen Tricuspid Regurgitation (TR)

In the ATLAS prospective, randomized trial comparing lead-related complications of S-ICD to TV-ICD, there was evidence as early as 6 months after implant that patients with a transvenous lead had significant worsening of their TR.⁷



Patients in the TV-ICD group were **seven times more likely** to have worsening TR ($p < 0.001$) than those in the S-ICD group.⁷




Of those patients with worsening TR, **three times as many patients with a TV-ICD (6.9%)** had moderate or severe TR vs patients with an S-ICD (2.3%) ($p = 0.02$)⁷

WHAT ABOUT ATP?

APPRAISE ATP and MODULAR ATP support offering S-ICD to Primary Prevention patients

In the APPRAISE ATP prospective, randomized trial, only 1% of Primary Prevention patients per year developed sustained VT amenable to ATP.²¹ In the near future, if a patient with an EMBLEM™ S-ICD device develops a need for ATP, it will be upgradeable to deliver painless ATP upon FDA approval of the EMPOWER™ LP* & mCRM™ system. *^{8,9}




WHAT IF PATIENT DEVELOPS NEED FOR BRADY PACING?

Current EMBLEM S-ICDs will be able to provide brady pacing in the future

Data from the MADIT II trial demonstrated that ~2% of Primary Prevention ICD indicated patients per year develop a new indication for brady pacing and that a baseline PR interval >200ms was significantly associated with the future need for brady pacing or CRT.²² In the near future if a patient with an EMBLEM™ S-ICD device develops a need for brady pacing, it will be upgradeable to deliver painless VVIR pacing upon FDA approval of the EMPOWER™ LP* & mCRM™ system.^{*8,9}

Device upgrades in the MADIT II trial during the 20-month median follow-up



Kutyifa V. et al. Ann Noninvasive Electrocardiol. Jul 2020;25(4): e12744.



IMPORTANCE OF MONITORING PATIENTS FOR NEW ONSET AFIB

S-ICD reduces the risk of serious complications with TV-ICD AND can also detect AFib


EMBLEM™ MRI S-ICD offers the AF Monitor feature, which is designed to assist in the detection of silent, new onset, or the progression of Atrial Fibrillation.²³



- Designed to detect silent, new onset, and progression of AF based on ventricular scatter and HR distribution²³
- Optimized for positive predictive value (PPV $\geq 90\%$) to decrease false positives²³
- Sensitivity: $\geq 87\%$ ²³

Real-World Performance of AF Monitor (AFM)

7,744 S-ICD devices were followed for up to 30 months via LATITUDE where 99.5% had AFM enabled and the positive predictive value was 67.7%.²⁴



EMBLEM™ MRI S-ICD

PROTECTION WITH REDUCED RISK

The EMBLEM™ MRI S-ICD is an ideal option for Primary Prevention patients, including those in their 50s and 60s who are at higher risk for infection and more serious complications. Over 20 years of data^{2-6, 12-15} show the S-ICD is as effective in preventing sudden cardiac death as a TV-ICD. Additionally, technology advancements to the S-ICD over the past 10 years support the device as an option for the majority of Primary Prevention patients.

All EMBLEM MRI S-ICD devices implanted today offer the following features:

- AF Monitor to detect new-onset atrial fibrillation^{23, 24}
- A median battery life of 8.7 years based on real-world data²⁵
- One-year inappropriate shock rates under 2% as demonstrated in recent studies with the SMART Pass feature activated and using the intermuscular implant technique^{26, 27}
- If a patient with an EMBLEM S-ICD device develops a need for ATP and/or brady pacing, all EMBLEM S-ICDs will be upgradeable to deliver painless ATP and VVIR pacing upon FDA approval of the EMPOWER LP* & mCRM system^{8, 9}



REFERENCES

- Knops RE, Peppinkhuizen S, Delnoy P, et al. Device-related complications in the subcutaneous and transvenous ICD: a secondary analysis of the PRAETORIAN trial. *Eur Heart J.* Aug 28, 2022; 43(47):4872-4883.
- Lambiase PD, Theuns DA, Murgatroyd F, et al. Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. *Eur Heart J.* 2022. Jan 28.
- Knops R. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: An Analysis of All Appropriate Therapy in the PRAETORIAN Trial. *Circulation.* 2022; 145:321-329.
- Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. *CIRCULATION* 2021;143(1):7-17.
- Gold MR, El-Chami MF, Burke MC, et al. Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System. *J Am Coll Cardiol.* Aug 1, 2023; 82(5):383-397.
- Healey JS, Krahn AD, Bashir J, et al. Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations: A Randomized, Multicenter Trial. *Ann Intern Med.* Nov 8 2022;175(12):1658-1665.
- Leong D DH, Mondesert BA, et al. Effects of Implantable Cardioverter-Defibrillator Leads on the Tricuspid Valve and Right Ventricle: A Randomized Comparison of Transvenous versus Subcutaneous Leads. *Heart Rhythm Society Late Breaking Clinical Trials.* May 19th 2023; LB-456090-02.
- Lloyd MS, Brisben AJ, Reddy VY, et al. Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator. *Heart Rhythm O2.* 2023;4(7):448-456. Published 2023 Jun 2.
- Knops RE, Lloyd MS, Roberts PR, et al. A Modular Communicative Leadless Pacing-Defibrillator System. *N Engl J Published online May 18, 2024.* doi:10.1056/NEJMoa2401807.
- Jones NR, Roalke AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. *Eur J Heart Fail.* Nov 2019;21(11):1306-1325.
- Koneru, JN, Jones, PW, Hammill, EF, Wold, N, and Ellenbogen, KA, Risk Factors and Temporal Trends of Complications Associated With Transvenous Implantable Cardiac Defibrillator Leads. *J Am Heart Assoc.* 2018. 7(10).
- Al-Khatib SM, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm.* 2018; 15(10): e190-e252.
- Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J.* 2015 Nov 1;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29. PMID: 26320108.
- Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med.* 2010; 363:36-44 (78 patients; Sept. 2001-Feb. 2004).
- Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. *N Engl J Med.* Aug 6 2020;383(6):526-536.
- Blatt, JA et al. No Benefit from Defibrillation Threshold Testing in SCD-HeFT. *J Am Coll Cardiol.* 2008.52(7):551-6.
- Swerdlow, CD et al. The Dilemma of ICD Implant Testing. *Pace.* 2007; 30: 675-700.
- Kutyifa, V. et al. Clinical Impact, Safety, and Efficacy of Single- versus Dual-Coil ICD Leads in MADIT-CRT. *J Cardiovasc Electrophysiol* 2013;24(11):1246-52.
- Hosseini SM, Rozen G, Kaadan MI, Galvin J, Ruskin JN. Safety and In-Hospital Outcomes of Transvenous Lead Extraction for Cardiac Implantable Device-Related Infections: Analysis of 13 Years of Inpatient Data in the United States. *JACC Clin Electrophysiol.* Dec 2019; 5(12):1450-1458.
- Vio R, Forlin E, Culic V, Themistodakis S, Proietti R, China P. Systematic Review on S-ICD Lead Extraction. *J Clin Med.* May 27 2023;12(11) doi:10.3390/jcm12113710.
- Schuger C. et al. Assessment of Primary Prevention Patients Receiving An ICD- Systematic Evaluation of ATP. APPRAISE ATP. *Heart Rhythm Society Late Breaking Clinical Trials and Science LB-469803-02.* 2024.
- Kutyifa V, Rosero SZ, McLitt S, et al. Need for pacing in patients who qualify for an implantable cardioverter-defibrillator: Clinical implications for the subcutaneous ICD. *Ann Noninvasive Electrocardiol.* Jul 2020;25(4): e12744.
- EMBLEM S-ICD, EMBLEM MRI S-ICD User's Manual, 92346911-002 EN-US 2021-09
- Baalman SWE, Mittal S, Boersma LVA, et al. Real-world performance of the atrial fibrillation monitor in patients with a subcutaneous ICD. *Pacing Clin Electrophysiol.* Dec 2020;43(12):1467-1475.
- van der Stuijt, W, Williams JL, Brisben AJ, et al. Real world battery longevity of the subcutaneous implantable cardioverter-defibrillator (S-ICD). *European Heart Journal.* 2023;44(Supplement_2) doi:10.1093/eurheartj/ehad655.684.
- Boersma LVA, Aasbo J, Knops RE, et al. The impact of SMART pass algorithm status on inappropriate shock rates in the UNTOUCHED Study. *EP Europace.* 2022;24 (Supp 1): eua053.39.
- Botto GL, Ziacchi M, Nigro G, et al. Intermuscular technique for implantation of the subcutaneous implantable defibrillator: a propensity-matched case-control study. *Europace.* 2023;25(4):1423-1431.

EMBLEM™ MRI S-ICD System

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" and MRI Technical Guide for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions. **INDICATIONS FOR USE:** The S-ICD System is intended to provide defibrillation therapy for the treatment of life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with anti-tachycardia pacing. **CONTRAINDICATIONS:** Unipolar stimulation and impedance-based features are contraindicated for use with the S-ICD System. **WARNINGS:** • Concomitant use of the S-ICD System and implanted electro-mechanical devices (for example implantable neuromodulation/neurostimulation systems, ventricular assist device (VAD), or implantable insulin pump or drug pump) can result in interactions that could compromise the function of the S-ICD, the co-implanted device, or both. The S-ICD is intended as lifesaving therapy and should be seen as priority in the decision and evaluation of concomitant system implants over non-lifesaving applications. Electromagnetic (EMI) or therapy delivery from the co-implanted device can interfere with S-ICD sensing and/or rate assessment, resulting in inappropriate therapy or failure to deliver therapy when needed. In addition, a shock from the S-ICD pulse generator could damage the co-implanted device and/or compromise its functionality. Verify sensing configuration, operation modes, surgical considerations and existing placement of all involved devices prior to any co-implant. To help prevent undesirable interactions, test the S-ICD system when used in combination with the co-implanted device, and consider the potential effect of a shock on the co-implanted device. Induction testing is recommended to ensure appropriate detection and time to therapy for the S-ICD and appropriate post-shock operation of the co-implanted device. Failure to ensure appropriate detection and time to therapy delivery of the S-ICD system could result in patient injury or death. • Following completion of the interaction testing, thorough follow-up evaluation of all co-implanted devices should be performed to ensure that device functions have not been compromised. If operational settings of the co-implanted devices change or if patient conditions changes which may affect S-ICD sensing and therapy performance, re-evaluation of the co-implanted devices may be required. • All Boston Scientific S-ICD implantable components are designed for use with the Boston Scientific or Cameron Health S-ICD System only. Connection of any S-ICD System components to a non-compatible component has not been tested and could result in failure to deliver life-saving defibrillation therapy. • Always have external defibrillation equipment and medical personnel skilled in CPR available during implant and follow-up testing. If not terminated in a timely fashion, an induced ventricular tachyarrhythmia can result in the patient's death. • Using multiple pulse generators could cause pulse generator interaction, resulting in patient injury or a lack of therapy delivery. Test each system individually and in combination to help prevent undesirable interactions. Refer to "S-ICD System and Pacemaker Interaction" on page 73 for more information. • Attention is required to placement of the arm ipsilateral to the device implant to avoid injury of the ulnar nerve and brachial plexus while the patient is in the supine position during device implantation and before VF induction or shock delivery. The patient should be positioned with the arm abducted to an angle of no more than 60° with the hand in a supinated (palm up) position during the implant phase of the procedure. Securing the arm to an arm board is standard practice to maintain positioning of the arm during device implantation. Do not strap the arm too tightly during defibrillation testing. Elevation of the torso through use of a wedge may also add stress to the shoulder joint and should be avoided during defibrillation testing. • Use appropriate anchoring techniques as described in the implant procedure to prevent S-ICD System dislodgement and/or migration. Dislodgement and/or migration of the S-ICD System may result in an inappropriate shock or failure to deliver therapy to the patient. • Use caution when placing a magnet over the S-ICD pulse generator because it suspends arrhythmia detection and therapy response. Removing the magnet resumes arrhythmia detection and therapy response. • In patients with a deep implant placement (greater distance between the magnet and the pulse generator), magnet application may fail to elicit the magnet response. In this case the magnet cannot be used to inhibit therapy. • Advise patients to seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator. • High shocking electrode impedance may reduce VT/VF conversion success. • When positioning the electrode and pulse generator, avoid excessive tension on the electrode, particularly if the electrode body extends over the pulse generator. This could cause structural damage, abrasion, and/or conductor discontinuity. • Although pliable, the electrode is not designed to tolerate excessive flexing, tight radius bending, kinking, or twisting. This could cause structural damage, conductor discontinuity, electrode migration, and/or dislodgement. • Electrode fracture, abrasion, under-insertion of the electrode connector into the pulse generator connector port, or a loose setscrew connection may result in compromised sensing, loss of therapy, or inappropriate therapy. • Following any sensing parameter adjustment or any modification of the subcutaneous electrode, always verify appropriate sensing. • Determine if the device and programmed parameters are appropriate for patients with SVTs because SVTs can initiate unwanted device therapy. • During a device software update, tachycardia therapy is suspended. Always monitor the patient and have external defibrillation equipment available during interrogation. • Do not expose a patient with an implanted S-ICD System to diathermy. • EMBLEM S-ICD devices are considered MR Conditional. Unless all MRI Conditions of Use are met, MRI scanning of the patient does not meet MR Conditional requirements for the implanted system. • The Programmer is MR Unsafe and must remain outside the MRI site Zone III (and higher) as defined by the American College of Radiology Guidance Document on MR Safe Practices. • During MRI Protection Mode the Tachycardia therapy is suspended. • MRI scanning after ERI status has been reached may lead to premature battery depletion, a shortened device replacement window, or sudden loss of therapy. • The Beeper may no longer be usable following an MRI scan. • The pulse generator may be more susceptible to low frequency electromagnetic interference at induced signals greater than 80 uV. • Immersion in saltwater and similar conductive fluid environments (i.e. ocean, saltwater pools) may divert some defibrillation shock energy away from the patient's heart into the surrounding conductive fluid (as evidenced by a lower-than-normal shock impedance). This may reduce VT/VF conversion success, especially in patients with low BMI. **PRECAUTIONS:** For specific information on precautions, refer to the following sections of the product labeling: clinical considerations, sterilization and storage, implantation, device programming, environmental and medical therapy hazards, hospital and medical environments, home and occupational environments, follow up testing, explant and disposal, supplemental precautionary information. • The S-ICD System has not been evaluated for pediatric use. • The S-ICD System does not provide long-term bradycardia pacing, cardiac resynchronization therapy (CRT), or antitachycardia pacing (ATP). • When implanting the S-ICD system in a patient with sternal wires, ensure that there is no contact between the sternal wires and the distal and proximal sense electrodes (for example, by using fluoroscopy). Compromised sensing can occur if metal-to-metal contact occurs between a sense electrode and a sternal wire. If necessary, re-tunnel the electrode to ensure sufficient separation between the sense electrodes and the sternal wires. • Implanting a replacement device in a subcutaneous pocket that previously housed a larger device may result in pocket air entrapment, migration, erosion, or insufficient grounding between the device and tissue. Irrigating the pocket with sterile saline solution decreases the possibility of pocket air entrapment and insufficient grounding. Suturing the device in place reduces the possibility of migration and erosion. **Electromagnetic Interference (EMI) Precautions:** • Avoid electromagnetic interference (EMI). Advise patients to avoid sources of EMI because EMI may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy. • Moving away from the source of the EMI or turning off the source usually allows the pulse generator to return to normal operation. • Examples of potential EMI sources are: o Electrical power sources o Arc welding or resistance welding equipment (should remain at least 24 inches from the implant) o Robotic jacks o High voltage power distribution lines o Electrical smelting furnaces o Large RF transmitters such as radar o Radio transmitters, including those used to control toys o Electronic surveillance (antitheft) devices o An alternator on a car that is running o Medical treatments and diagnostic tests in which an electrical current is passed through the body, such as TENS, electrocautery, electrolysis/thermolysis, electrodiagnostic testing, electromyography, or nerve conduction studies o Any externally applied device that uses an automatic lead detection alarm system (e.g., an EKG machine) • Home appliances. Home appliances that are in good working order and properly grounded do not usually produce enough EMI to interfere with pulse generator operation. There have been reports of pulse generator disturbances caused by electric hand tools or electric razors used directly over the pulse generator implant site. • Electronic Article Surveillance (EAS) and security systems. Advise patients how to avoid impact to cardiac device function due to antitheft and security gates, tag deactivators, or tag readers that include radio frequency identification (RFID) equipment. These systems may be found at the entrances and exits of stores, at checkout counters, in public libraries, and in point-of-entry access control systems. Patients should avoid lingering near or leaning against antitheft and security gates and tag readers. In addition, patients should avoid leaning against checkout counter-mounted and handheld tag deactivation systems. Antitheft gates, security gates, and entry control systems are unlikely to affect cardiac device function when patients walk through them at a normal pace. If the patient is near an electronic antitheft, security, or entry control system and experiences symptoms, they should promptly move away from nearby equipment and inform their doctor. • Cellular phones. Patients should not carry a cellular phone within 15 cm (6 inches) of the implanted device in order to avoid interaction which may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy. Advise patients to hold cellular phones to the ear opposite the side of the implanted device, and to avoid storing a cellular phone within 15 cm (6 inches) of the implanted device. Examples of storage locations to be avoided include a breast or other shirt pocket, on a belt, or in a handbag held near the implant location. • Static magnetic fields. Advise patients that extended exposure to strong (greater than 10 gauss or 1 mTesla) magnetic fields may suspend arrhythmia detection. Examples of permanent magnet-containing sources to be aware of include: o Industrial motors if held within 60 cm (24 inches) of the pulse generator o MRI scanners o Large stereo speakers if held within 60 cm (24 inches) of the pulse generator o Telephone receivers if held within 1.27 cm (0.5 inches) of the pulse generator o Magnetic wands such as those used for airport security and in the Bingo game o Cellular phones, ear buds, or headphones, if held within 15 cm (6 inches) of the pulse generator o Magnetically attached charging port or cable, such as used in laptops or cellular phones, if held within 15 cm (6 inches) of the pulse generator o Be aware of other body-worn items which may contain magnets, such as wrist bands, jewelry, clothing, nametags, CPAP masks, etc. **POTENTIAL ADVERSE EVENTS:** Potential adverse events related to implantation of the S-ICD System may include, but are not limited to, the following: • Acceleration/induction of atrial or ventricular arrhythmia • Adverse reaction to induction testing • Allergic/adverse reaction to system or medication • Bleeding • Conductor fracture • Cyst formation • Death • Delayed therapy delivery • Discomfort or prolonged healing of incision • Electrode deformation and/or breakage • Electrode insulation failure • Erosion/extrusion • Failure to deliver therapy • Fever • Hematoma/seroma • Hemorrhax • Improper electrode connection to the device • Inability to communicate with the device • Inability to defibrillate or pace • Inappropriate post-shock pacing • Inappropriate shock delivery • Infection • Injury to or pain in upper extremity, including clavicula, shoulder, and arm • Keloid formation • Migration or dislodgement • Muscle/nerve stimulation • Nerve damage • Organ injury or perforation • Pneumothorax • Post-shock/post-pace discomfort • Premature battery depletion • Random component failures • Stroke • Subcutaneous emphysema • Surgical revision or replacement of the system • Syncope • Tissue damage • Tissue redness, irritation, numbness or necrosis • Vessel injury or perforation. Transient procedural adverse events are expected in some patients. These include, but are not limited to, discomfort, pain and other systemic symptoms that might be related to medications or other interventions performed during implant. **Patients who receive an S-ICD System** may develop psychological disorders that include, but are not limited to, the following: • Depression/anxiety • Fear of device malfunction • Fear of shocks • Phantom shocks. 92436235 Ver B

Boston Scientific
Advancing science for life™

Cardiology
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

Medical Professionals:
1.800.CARDIAC (227.3422)
Customer Service:
1.866.484.3268

© 2024 Boston Scientific Corporation
or its affiliates. All rights reserved.

CRM-1963202-AA

